| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6010718 | ABBVIE | Extended release formulations of erythromycin derivatives |
Apr, 2017
(7 years ago) | |
| US6551616 | ABBVIE | Extended release formulations of erythromycin derivatives |
Jul, 2017
(6 years ago) | |
Biaxin Xl is owned by Abbvie.
Biaxin Xl contains Clarithromycin.
Biaxin Xl has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Biaxin Xl are:
- US6010718
- US6551616
Biaxin Xl was authorised for market use on 03 March, 2000.
Biaxin Xl is available in tablet, extended release;oral dosage forms.
Biaxin Xl can be used as treatment of mild to moderate infection caused by susceptible strains.
The generics of Biaxin Xl are possible to be released after 15 July, 2017.
Drugs and Companies using CLARITHROMYCIN ingredient
Market Authorisation Date: 03 March, 2000
Treatment: Treatment of mild to moderate infection caused by susceptible strains
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of BIAXIN XL before it's drug patent expiration?
More Information on Dosage
BIAXIN XL family patents
